XBiotech (XBIT) Accounts Payables (2014 - 2026)

XBiotech has reported Accounts Payables for 13 years, with the latest figure at $1.1 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 22.78% year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was $1.1 million, a 22.78% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 30.95% from the prior year.
• Accounts Payables was $1.1 million for Q2 2026 at XBiotech, down from $1.5 million in the prior quarter.
• The five-year high for Accounts Payables was $2.6 million in Q1 2024, with the low at $1.0 million in Q3 2025.
• Average Accounts Payables over 5 years is $1.7 million, with a median of $1.5 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 92.11% in 2024, then plunged 57.81% in 2025.
• Over 5 years, Accounts Payables stood at $2.4 million in 2022, then rose by 4.49% to $2.5 million in 2023, then declined by 11.65% to $2.2 million in 2024, then tumbled by 30.95% to $1.5 million in 2025, then declined by 28.01% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q2 2026), $1.5 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.